Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 1551 - 1600 of 3753 results
- Chymase increases glomerular albumin permeability via protease-activated receptor-2.
- A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.
- Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
- Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
- Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.
- Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
- Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
- Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
- Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.
- C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
- Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo.
- Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.
- Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques.
- Characteristics and six-month outcomes in a cohort of 8288 diabetic and non-diabetic patients with previous history of acute coronary syndrome or stroke: the French PREVENIR 3 survey.
- Cardiovascular risk markers associated with the metabolic syndrome in a large French population: the "SYMFONIE" study.
- Oral combination therapy with thiazolidinediones in type 2 diabetes.
- Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: Indoline compounds as potent DPP-IV inhibitors.
- Loss of invariant chain protects nonobese diabetic mice against type 1 diabetes.
- Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.
- Insulin protects against stress-induced impairments in water maze performance.
- Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.
- A meta-analysis of diabetes mellitus and the risk of prostate cancer.
- Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice.
- Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension.
- Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling.
- Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1.
- 6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist.
- Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.
- Novel carbazole derivatives as NPY Y1 antagonists.
- Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia.
- Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.
- v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation.
- Design and synthesis of a novel class of dual PPARgamma/delta agonists.
- Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
- Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
- Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
- The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey.
- Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study.
- Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.
- Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.
- Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes.
- The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
- OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization.
- Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance.
- C-Peptide reverses nociceptive neuropathy in type 1 diabetes.
- Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.
- Using intranasal lidocaine to reduce food intake.
- Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys.
- Connective tissue growth factor (CTGF/CCN2) is a downstream mediator for TGF-beta1-induced extracellular matrix production in osteoblasts.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >